Tempus AI (Nasdaq: TEM) announced an expanded, multi-year collaboration with Moderna (Nasdaq: MRNA) and Merck (NYSE: MRK) to support the potential commercialization of intismeran autogene (V940/mRNA-4157), an investigational personalized cancer vaccine being developed in combination with pembrolizumab (Keytruda). Financial terms were not disclosed.
Under the agreement, Tempus will coordinate the collection and transfer of tumor tissue and blood samples for next-generation sequencing (NGS) and, subject to regulatory approvals, provide sequencing services to support the design and manufacturing of individualized treatments. The collaboration expands on joint efforts initiated in 2025.
The agreement follows positive Phase III results from the INTerpath-001 trial in August 2026, when Moderna and Merck reported that intismeran autogene plus Keytruda met the primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in patients with completely resected stage IIB–IV melanoma. The companies plan to engage regulators on potential marketing applications.
Earlier, five-year follow-up data from the Phase IIb KEYNOTE-942 trial showed that the combination reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 59% compared with Keytruda alone in patients with resected stage III/IV melanoma.